Patents by Inventor Ron Neumann

Ron Neumann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Glaucoma Using Laquinimod
    Publication number: 20180140593
    Abstract: The subject invention provides a method of treating a subject afflicted with glaucoma, suffering from retinal ganglion cell (RGC) loss or damage, or elevated intraocular pressure (IOP), or of reducing RGC loss or damage, or reducing IOP in a subject, comprising administering to the subject an amount of laquinimod effective to treat the subject, to reduce RGC loss or damage, or to reduce IOP in the subject. Provide also is a pharmaceutical composition, a package and a therapeutic package for treating a subject afflicted with glaucoma.
    Type: Application
    Filed: January 19, 2018
    Publication date: May 24, 2018
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Ron Neumann, Revital Etzyoni
  • Treatment of Glaucoma Using Laquinimod
    Publication number: 20170368054
    Abstract: The subject invention provides a method of treating a subject afflicted with glaucoma, suffering from retinal ganglion cell (RGC) loss or damage, or elevated intraocular pressure (IOP), or of reducing RGC loss or damage, or reducing IOP in a subject, comprising administering to the subject an amount of laquinimod effective to treat the subject, to reduce RGC loss or damage, or to reduce IOP in the subject. Provide also is a pharmaceutical composition, a package and a therapeutic package for treating a subject afflicted with glaucoma.
    Type: Application
    Filed: September 11, 2017
    Publication date: December 28, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Ron Neumann, Revital Etzyoni
  • Treatment of Glaucoma Using Laquinimod
    Publication number: 20170266179
    Abstract: The subject invention provides a method of treating a subject afflicted with glaucoma, suffering from retinal ganglion cell (RGC) loss or damage, or elevated intraocular pressure (IOP), or of reducing RGC loss or damage, or reducing IOP in a subject, comprising administering to the subject an amount of laquinimod effective to treat the subject, to reduce RGC loss or damage, or to reduce IOP in the subject. Provide also is a pharmaceutical composition, a package and a therapeutic package for treating a subject afflicted with glaucoma.
    Type: Application
    Filed: June 1, 2017
    Publication date: September 21, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Ron Neumann, Revital Etzyoni
  • Treatment of Glaucoma Using Laquinimod
    Publication number: 20170128436
    Abstract: The subject invention provides a method of treating a subject afflicted with glaucoma, suffering from retinal ganglion cell (RGC) loss or damage, or elevated intraocular pressure (IOP), or of reducing RGC loss or damage, or reducing IOP in a subject, comprising administering to the subject an amount of laquinimod effective to treat the subject, to reduce RGC loss or damage, or to reduce IOP in the subject. Provide also is a pharmaceutical composition, a package and a therapeutic package for treating a subject afflicted with glaucoma.
    Type: Application
    Filed: January 24, 2017
    Publication date: May 11, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Ron Neumann, Revital Etzyoni
  • Treatment of Glaucoma Using Laquinimod
    Publication number: 20170027927
    Abstract: The subject invention provides a method of treating a subject afflicted with glaucoma, suffering from retinal ganglion cell (RGC) loss or damage, or elevated intraocular pressure (IOP), or of reducing RGC loss or damage, or reducing IOP in a subject, comprising administering to the subject an amount of laquinimod effective to treat the subject, to reduce RGC loss or damage, or to reduce IOP in the subject. Provide also is a pharmaceutical composition, a package and a therapeutic package for treating a subject afflicted with glaucoma.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 2, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Ron Neumann, Revital Etzyoni
  • Treatment of Glaucoma Using Laquinimod
    Publication number: 20150141458
    Abstract: The subject invention provides a method of treating a subject afflicted with glaucoma, suffering from retinal ganglion cell (RGC) loss or damage, or elevated intraocular pressure (IOP), or of reducing RGC loss or damage, or reducing IOP in a subject, comprising administering to the subject an amount of laquinimod effective to treat the subject, to reduce RGC loss or damage, or to reduce IOP in the subject. Provide also is a pharmaceutical composition, a package and a therapeutic package for treating a subject afflicted with glaucoma.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 21, 2015
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Ron Neumann, Revital Etzyoni
  • Method of treating glaucoma using rasagiline
    Publication number: 20090062400
    Abstract: Disclosed is a method of reducing glaucoma in a subject afflicted with glaucoma, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptably salt thereof effective to reduce glaucoma.
    Type: Application
    Filed: September 3, 2008
    Publication date: March 5, 2009
    Inventors: Laurence Oron, Cheryl Fitzer-Attas, Ron Neumann